This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Sage Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.441. Sage Therapeutics's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.
As of today (2024-04-24), Sage Therapeutics's share price is $12.95. Sage Therapeutics's Median PS Value is $0.00. Therefore, Sage Therapeutics's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Sage Therapeutics's Median PS Value or its related term are showing as below:
SAGE's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.66 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Sage Therapeutics Median PS Value Historical Data
The historical data trend for Sage Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sage Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sage Therapeutics Price-to-Median-PS-Value Distribution
For the Biotechnology industry and Healthcare sector, Sage Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Sage Therapeutics's Price-to-Median-PS-Value falls into.
Sage Therapeutics Median PS Value Calculation
Sage Therapeutics's Median PS Value for today is calculated as
10-Year Median PS Ratio is 0.
Sage Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.441.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sage Therapeutics (NAS:SAGE) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Sage Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
12.95
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sage Therapeutics Median PS Value Related Terms
Thank you for viewing the detailed overview of Sage Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Sage Therapeutics (Sage Therapeutics) Business Description
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SAGE has been successfully added to your 